Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model
about
The Structure of the Poxvirus A33 Protein Reveals a Dimer of Unique C-Type Lectin-Like DomainsAntibodies for biodefenseA comparison of binding surfaces for SPR biosensing using an antibody-antigen system and affinity distribution analysis.Progress towards recombinant anti-infective antibodies.Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis.Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.The inability of vaccinia virus A33R protein to form intermolecular disulfide-bonded homodimers does not affect the production of infectious extracellular virus.Epitope mapping by random peptide phage display reveals essential residues for vaccinia extracellular enveloped virion spread.Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections.Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases.Chimpanzees as an animal model for human norovirus infection and vaccine development.Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsuleDevelopment of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis.Smallpox vaccines: targets of protective immunity.Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.Susceptibility of Marmosets (Callithrix jacchus) to Monkeypox Virus: A Low Dose Prospective Model for Monkeypox and Smallpox Disease.Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer.Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine.Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding SiteBayesian analysis of heterogeneity in the distribution of binding properties of immobilized surface sitesTherapeutic and prophylactic drugs to treat orthopoxvirus infectionsActive vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complementHeavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5.The smallpox vaccine induces an early neutralizing IgM response.Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.Serro 2 Virus Highlights the Fundamental Genomic and Biological Features of a Natural Vaccinia Virus Infecting Humans.Protective murine and human monoclonal antibodies against eczema vaccinatum
P2860
Q27658759-991B7BE1-5D58-4C06-B8BC-6DD520038D78Q28394941-0CA6E6E7-01F4-4479-A23A-8BBF4CC0437EQ30557856-614AF24B-1676-47E1-8B3D-37BE17B63FF9Q33568256-380490D3-A9A1-40B4-B36E-EAE889BFE1D1Q33827773-B3A189B3-E62C-403E-9A02-8640B071D98CQ33967713-7F4B7306-33B4-4740-A116-7AC9E66C60A3Q34312168-46273229-792E-40CB-850A-01F0AB4015B4Q34420319-88E5EE4E-C346-4768-B3CF-BEF108EAF3F9Q34447009-BBCC2CF7-4EF2-4984-A159-BB4061F9EA5CQ34457869-547608D9-1065-4626-A267-1FAFD12424B7Q34471908-DB7AE59D-99A7-406E-B72E-A826A441986BQ34490786-98FEED88-7245-4D10-87DD-D8C14C71E546Q34778430-E883AE7D-90BD-45EA-A6F1-E9DD1BDC3403Q34780607-37083DDD-E84A-4E61-B62B-FEC7C0E4DF1EQ35339702-C6B65D26-537B-439C-BDC0-4EF02CF23035Q35683735-713EB3E5-490B-4100-B926-D63143A6831CQ35760869-F02281F5-04CC-46AA-8458-D7AF8EAF56C3Q36559797-538A7D45-8C19-4710-9E15-5FC34C9841CBQ36590540-440ED2A6-C0AA-42BF-829A-99CDC04C0C91Q36953458-3A131775-02BB-4B1E-A7C6-F165EC4CC297Q37009973-B477277E-B880-4481-AF22-43574947ED9CQ37042331-E446B27B-91EF-4AC4-A4DB-E24E91215969Q37051617-BA559789-B86C-46A1-8F60-D26F0472BC28Q37452067-D57412C6-D7C8-49AC-B722-AE415D08E448Q37456873-802D0FC2-A30B-4CDF-B709-48F69AD18DF0Q37461110-9DA10C68-62B1-4C0E-A505-2EF719EC266EQ37539293-3C8C8F1F-003B-4C2B-9D09-E09375946E70Q42638248-C6EB2F74-C882-4AC6-B544-F5900B804118
P2860
Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Characterization of chimpanzee ...... a virus mouse protection model
@ast
Characterization of chimpanzee ...... a virus mouse protection model
@en
type
label
Characterization of chimpanzee ...... a virus mouse protection model
@ast
Characterization of chimpanzee ...... a virus mouse protection model
@en
prefLabel
Characterization of chimpanzee ...... a virus mouse protection model
@ast
Characterization of chimpanzee ...... a virus mouse protection model
@en
P2093
P2860
P356
P1433
P1476
Characterization of chimpanzee ...... a virus mouse protection model
@en
P2093
Andrew Sebrell
Gary Cohen
Inger Damon
Inna Gorshkova
Jeffrey Americo
Patricia Earl
Peter Schuck
Robert Purcell
Scott K Smith
P2860
P304
P356
10.1128/JVI.00906-07
P407
P577
2007-06-20T00:00:00Z